Advertisement

The AAPS Journal

, 21:52 | Cite as

Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species

  • Chuenlei ParngEmail author
  • Michael Bolt
  • Debra D. Pittman
  • Teresa Caiazzo
  • Lisa Dyleski
  • Boris Gorovits
  • Rob Webster
Research Article

Abstract

This paper presents a systemic investigation of ADA development and ADA impact of a human coagulation factor in nonclinical species during drug development and provides insights into potential implications in human if a similar ADA occurs. FXaI16L-induced ADA response was characterized in monkey, mouse, rat, and dog in different studies, and ADA effects on pharmacokinetic and/or pharmacodynamics of FXaI16L were further examined in ADA-negative and ADA-positive animals. After repeated administrations, FXaI16L elicited a dose and exposure day-dependent ADA response which ranged from no response to a transient or persistent response. Increase in exposure day and increase in dose generally enhanced ADA incidence except for a decrease in ADA incidence was observed in monkeys after repeated high-dose administrations. The observable ADA impact on pharmacokinetics was only found in some ADA+ animals and included decrease in clearance and increase in systemic exposure but no increase in half-life. In addition, no or limited effect on pharmacodynamics by ADA was observed. The earliest ADA response was observed after three exposure days, marked elevation of drug exposure was observed in some animals at log titer > 2.0, and the highest antibody titer excited was about 4 (Log10) in all species. A correlation between ADA induction and accumulative exposure after various repeat treatments in different species was found for FXaI16L. In addition, potential immunogenicity risk and mitigation of ADA in clinics are discussed.

KEY WORDS

anti-drug antibody coagulation factor exposure day FXaI16L hemophilia inhibitor neutralizing antibody 

Abbreviations

ADA

Anti-drug antibody

AUC

Area under the curve

Cmax

Maximum observed concentration

EGRCK

Glu-Gly-Arg-chloromethyl ketone

FEIBA

Factor eight inhibitor bypassing agent (anti-inhibitor coagulant complex)

FXa

Active coagulation factor X

nAb

Neutralizing antibody

PK

Pharmacokinetics

PD

Pharmacodynamics

Notes

Acknowledgements

All of the authors are Pfizer employees and FXaI16 is a Pfizer clinical candidate. We thank all the support and guidance from the Pfizer FXaI16L development team. We also thank all the colleagues involved in development of FXaI16L in Pfizer whose dedication made all the studies possible.

References

  1. 1.
    De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28:482–90.CrossRefGoogle Scholar
  2. 2.
    Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333:1–9.CrossRefGoogle Scholar
  3. 3.
    Tovey MG. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Safety. 2011;3:133–28.Google Scholar
  4. 4.
    Sorensen PS, Ross C, Clemmesen KM, Bendtaen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184–91.CrossRefGoogle Scholar
  5. 5.
    Scgnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interf Cytokine Res. 2002;22:207–13.CrossRefGoogle Scholar
  6. 6.
    Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematol Educ Program. 2016;2016(1):657–62.CrossRefGoogle Scholar
  7. 7.
    Gouw SC, van der Bom JG, Van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: the CANAL cohort study. Blood. 2007;109:4648–54.CrossRefGoogle Scholar
  8. 8.
    Hermans C, Astermark J, De Moerloose P. Exposure to factor VIII and prediction of inhibitor development exposure days vs danger days or both? J Thromb Haemost. 2012;10:2194–6.CrossRefGoogle Scholar
  9. 9.
    Hedner U. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia. 2010;17:172–82.CrossRefGoogle Scholar
  10. 10.
    Lamberth K, Weldingh KN, Ehrenforth S, Chéhadé MR, Østergarrd H. Immunogenicity lessons learned from the clinical development of Vatreptacog alpha, a recombinant activated factor VII analog, in hemophilia with inhibitor. Top Med Chem. 2017;20:123–60.CrossRefGoogle Scholar
  11. 11.
    Mahlangu JN, Koh PL, Ng HJ, Lissitchkov T, Hardtke M, Schroeder J. The TRUST trial: anti-drug antibody formation in a patient with hemophilia with inhibitors after receiving the activated factor VII product bay 86–6150. In: Presented at 55th annual meeting of the American Society of Hematology 2013; Abstrat 573.Google Scholar
  12. 12.
    Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman DD, Arkin S. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics and pharmacodynamics of a recombinant factor Xa variant (FXaI16L). J Thromb Haemost. 2017;15(5):931–7.CrossRefGoogle Scholar
  13. 13.
    Bunce MW, Toso R, Camire RM. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood. 2011;117(1):290–8.CrossRefGoogle Scholar
  14. 14.
    Parng C, Markiewicz V, Chen J, Leary B, Duriga N, Dyleski L, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution and interspecies scaling of recombinant human coagulation factor FXaI16L. J Pharm Sci. 2017;106:2136–43.CrossRefGoogle Scholar
  15. 15.
    Toso R, Zhu RH, Camire R. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. JBC. 2008;283(27):18627–35.CrossRefGoogle Scholar
  16. 16.
    Bolt M, Hua F, Brenneman K, Graves J, Arkin S, Criswell K. Evaluation of potential safety biomarkers for monitoring thrombogenic potential of FXaI16L. Blood. 2014;124:4237.Google Scholar
  17. 17.
    Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185–9.CrossRefGoogle Scholar
  18. 18.
    Reinisch W. Eser A, Schreiber S, Kim H, Mould D. Clinical: therapy and observation. Reduction of dosing intervals is the preferable dose optimisation strategy for infliximab to suppress formation of anti-drug antibodies. 2018;401.Google Scholar
  19. 19.
    Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia. 2010;16:256–62.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Pfizer Biomedicine Design, Pharmacokinetics Pharmacodynamics MetabolismCambridgeUSA
  2. 2.Pfizer Drug Safety Research and DevelopmentCambridgeUSA
  3. 3.Pfizer Rare Disease Research UnitCambridgeUSA
  4. 4.Pfizer Biomedicine DesignAndoverUSA

Personalised recommendations